Indaptus Therapeutics, Inc.
INDP
$0.4649
-$0.0151-3.15%
NASDAQ
12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 8.11M | 8.57M | 8.91M | 8.53M | 8.76M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 15.37M | 15.37M | 16.48M | 15.87M | 16.38M |
Operating Income | -15.37M | -15.37M | -16.48M | -15.87M | -16.38M |
Income Before Tax | -15.02M | -14.89M | -15.75M | -14.98M | -15.42M |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -15.02 | -14.89 | -15.75 | -14.98 | -15.42 |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -15.02M | -14.89M | -15.75M | -14.98M | -15.42M |
EBIT | -15.37M | -15.37M | -16.48M | -15.87M | -16.38M |
EBITDA | -15.37M | -15.37M | -16.48M | -15.86M | -16.38M |
EPS Basic | -1.62 | -1.72 | -1.86 | -1.78 | -1.84 |
Normalized Basic EPS | -1.01 | -1.08 | -1.17 | -1.11 | -1.15 |
EPS Diluted | -1.62 | -1.72 | -1.86 | -1.78 | -1.84 |
Normalized Diluted EPS | -1.01 | -1.08 | -1.17 | -1.11 | -1.15 |
Average Basic Shares Outstanding | 37.42M | 34.90M | 33.79M | 33.65M | 33.60M |
Average Diluted Shares Outstanding | 37.42M | 34.90M | 33.79M | 33.65M | 33.60M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |